We are submitting herewith the standalone and consolidated un-audited financial results under Regulation 33 of the Securities and Exchange board of India (Listing Obligations and Disclosure ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences India Ltd announced its unaudited Q1 FY26 results (quarter ended 30 June 2025), approved at the Board Meeting held on 14 August 2025. Standalone revenue from operations rose sharply by about 52% year-on-year to ₹2,453.18 lakhs (vs ₹1,617.67 lakhs in Q1 FY25), while consolidated revenue grew about 34% to ₹2,460.36 lakhs (vs ₹1,841.00 lakhs). Despite this strong top-line growth, the company reported continued losses, though they narrowed significantly: standalone loss for the period came in at ₹78.73 lakhs (vs ₹276.53 lakhs loss in Q1 FY25), and consolidated loss reduced to ₹200.62 lakhs (vs ₹307.30 lakhs). The pharmaceutical segment drove revenue growth but the printing and packaging subsidiary continued to drag on profitability. High finance costs (₹193.69 lakhs consolidated) remained a key pressure point. Statutory auditors Khurana Sharma & Co. issued an unmodified review opinion on both sets of results.
Positive signal from strong revenue growth and meaningful reduction in losses, suggesting improving operating efficiency. However, the company remains in the red with elevated interest costs, so sustained profitability and debt reduction will be key watchpoints for shareholders.